GlassScriptPhysician profile
Nolan D Ulrich
NPI 1659452209
$1,691.89
in general payments reported to CMS, 2019-2025
27 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.30 · 2020: $143 · 2021: $421 · 2022: $260 · 2023: $270 · 2024: $331 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.72 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $367.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $301.30 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $135.82 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $130.67 | 2023-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $118.94 | 2021-2023 | |
| Lilly USA, LLC | $93.87 | 2020-2023 | Mounjaro |
| Dexcom, INC. | $62.93 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.97 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $40.78 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $32.90 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $31.56 | 2024 | |
| Esperion Therapeutics, INC. | $30.35 | 2021 | |
| Allergan, INC. | $29.78 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.77 | 2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $24.76 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.14 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.82 | 2022 | |
| Axsome Therapeutics, INC. | $21.87 | 2024 | Auvelity |
| Amgen INC. | $21.77 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2024 | |
| Eisai INC. | $17.15 | 2020 | |
| Ardelyx, INC. | $16.23 | 2024 | Ibsrela |
| Teleflex LLC | $15.74 | 2025 | Quikclot |
| Boston Scientific Corporation | $14.41 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.30 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.10 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.61 | 2025 | Nuzyra, Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Ulrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.